Journal of lung cancer最新文献

{"title":"Histologic Features of ALK-Expressing Adenocarciomas of the Lung","authors":"H. Song, J. Jeong, Yoon-La Choi, Joungho Han","doi":"10.6058/JLC.2011.10.1.32","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.32","url":null,"abstract":"Purpose: This study was designed to define the specific histologic features of anaplastic lymphoma kinase (ALK)-expressing pulmonary adenocarcinoma. Materials and Methods: Of the 580 pulmonary adenocarcinomas diagnosed between March 2010 and February 2011, immunohistochemical staining for ALK was performed in 269 cases showing any suspicious histologic features in previous reports. The subtype according to the World Health Organization classification and the characteristic histologic features were re-evaluated in ALK-expressing cases. Results: A total of 46 cases (7.9% of the 580 adenocarcinomas, 17.1% of the 269 studied cases) were positive for ALK. Among the 46 cases showing ALK positivity, 35 cases (76%) showed intra- and/or extra-cytoplasmic mucin. The most well-known characteristic finding associated with ALK, signet ring cells, was found in 18 cases (39.1%). Cribriform pattern with extracytoplasmic mucin was identified in five cases. In six cases, all three features were found. On the other hand, there were three other cases that did not show any of the aforementioned histologic features. In 12 lobectomy specimens, the most common histologic pattern was a solid pattern (five cases, 41.6%). Conclusion: Intra- and/or extra-cytoplasmic mucin, including signet ring cell appearance and a cribriform pattern with extracytoplasmic mucin, are characteristic features of ALK-expressing non-small cell lung cancer. (J Lung Cancer 2011;10(1):32 �� 36)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 1","pages":"32-36"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.32","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Carcinoma with beta-Human Chorionic Gonadotropin Expression: Further Understanding and Suggestions for This Entity from Six Cases Experience in a Single Institution","authors":"Seung Eun Lee, J. Jeong, Joungho Han, C. Sung, Y. Choi","doi":"10.6058/JLC.2011.10.1.44","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.44","url":null,"abstract":"Purpose: β-human chorionic gonadotropin (β-hCG) expressing pulmonary carcinoma is very rare, and little is known about this entity. The aim of this study was to find the characteristic clinicopathologic features of β-hCG expressing pulmonary carcinoma. Materials and Methods: Of all 2790 lobectomy specimens of lung excised between January 2006 and December 2010, only six cases of β-hCG expressing pulmonary carcinoma were identified retrospectively. The cases were classified according to the WHO classification, and clinicopathologic features were investigated. Results: The patients consisted of 4 males and 2 females, and the median age was 64 years. Half of the patients presented with blood tinged sputum or hemoptysis. The median tumor diameter was 4.2 cm. All but one case showed prominent area of hemorrhage and necrosis. All six cases were pleomorphic carcinoma, composed of various types of non-small cell carcinomatous component and giant cell component. All cases showed significant area of β-hCG positivity, and β-hCG was usually expressed in the pleomorphic giant cells. Conclusion: In pulmonary carcinoma with pleomorphic giant cells, is necessary to check","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 1","pages":"44-48"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.44","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Tumor Cells in Lung Cancer","authors":"S. Yang, Y. Yang","doi":"10.6058/JLC.2011.10.1.13","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.13","url":null,"abstract":"Circulating Tumour Cells (CTCs) can be released from the primary lung tumour into the bloodstream and they may colonize distant organs and give rise to metastasis. The presence of CTCs in the blood has been documented more than a century ago, and ultrasensitive methods have been recently developed to detect circulating tumour cells (CTCs) in the peripheral blood of lung cancer patients. Most CTCs require an initial enrichment step, since CTCs are a very rare event. The different technologies and also the differences among the screened populations make the clinical significance of detecting CTCs difficult to interpret. Peripheral blood analyses are more convenient for patients than invasive BM sampling and many research groups are currently assessing the clinical utility of CTCs for assessing the prognosis and monitoring the response to systemic therapies in lung cancer patients. Here we will review the different assays that are currently available for CTC detection and analysis of lung cancer. Moreover, molecular analyses of CTCs have provided new insights into the biology of metastasis of lung cancer with important implications for the clinical management of lung cancer patients.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 1","pages":"13-25"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy","authors":"Shin‐Yup Lee, J. Park","doi":"10.6058/JLC.2011.10.1.1","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.1","url":null,"abstract":"Lung cancer is the leading cause of cancer death worldwide, with an overall 5 year survival rate of 15%. Most patients present with advanced disease that requires systemic chemotherapy, which merely confers several months of survival benefit. Recent advances in understanding the molecular mechanisms underlying lung cancer have led to molecular targeted therapy in this field. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first successful personalized therapy for non-small cell lung cancer (NSCLC), with about 30 months of median overall survival in patients with sensitive EGFR mutations. In addition, monoclonal antibodies against vascular endothelial growth factor (VEGF) or EGFR are also in current clinical use. Resistance to EGFR-TKIs has emerged as a major limitation of these agents and become challenge clinically. A number of novel targeted agents have been developed and investigated in clinical trials to overcome the limitation of agents currently available. Recently, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene ( EML4-ALK), as a novel molecular target of NSCLC, has been identified, and its inhibitor is under rapid clinical development. We herein review the molecular targeted therapies currently available for NSCLC and discuss the clinical data of novel agents under clinical development. (J Lung Cancer 2011;10(1):1 �� 12)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer","authors":"Junshik Hong, Y. Park, S. Lee, K. Lee, S. Park, Jinny Park, S. Sym, E. Cho, D. Shin, J. H. Lee","doi":"10.6058/JLC.2011.10.1.49","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.49","url":null,"abstract":"Purpose: To evaluate the antitumor activity and safety of irinotecan plus cisplatin combination chemotherapy with concurrent thoracic radiotherapy (TRT) in patients with limited disease (LD) small cell lung cancer (SCLC). Materials and Methods: Patients with pathologically-confirmed LD SCLC with the following inclusion criteria were retrospectively analyzed: age ≥18 years; measurable lesion; Eastern Cooperative Oncology Group Performance Status 0 ∼2; chemotherapy naive; and adequate bone marrow and organ function. Patients received an intravenous (IV) infusion of irinotecan (35 mg/m 2 on days 1, 8, and 15) and cisplatin (60 mg/m 2 on day 1), which was repeated every 4 weeks for up to 6 cycles. Concurrent TRT was administered with the beginning of chemotherapy. Irinotecan was increased to 60 mg/m2 after completion of TRT. Patients with a complete response (CR) subsequently received prophylactic cranial irradiation. Results: Nineteen patients were analyzed. There were 8 patients (42.1%) with CR, 9 patients (47.4%) with partial response, and 1 patient each (5.3%) with stable disease and progressive disease (PD). The overall response rate was 89.5%. The median progression-free survival was 7.6 months (95% confidence interval [CI], 1.3 ∼14.0 months) and the median overall survival was 12.4 months (95% CI, 0.5∼24.2 months). The 2-year survival rate of the CR patients was 75.0%. No grade 4 hematologic toxicity was reported. Frequently reported toxicities were nausea (10 patients), radiation-induced pneumonitis (10 patients), and neutropenia (6 patients). Radiation-related severe toxicities were frequently reported. Three patients had treatment-related deaths. Conclusion: This study supports the activity and tolerability of irinotecan plus cisplatin with concurrent TRT in patients with LD SCLC. (J Lung Cancer 2011;10(1):49 �� 55)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"28 1","pages":"49-55"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for Locoregional Recurrent Non-Small Cell Lung Cancer.","authors":"Mi Young Kim, J. Kim, J. Lee","doi":"10.6058/JLC.2011.10.1.37","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.37","url":null,"abstract":"Purpose: To retrospectively evaluate the outcomes and complications of curative radiotherapy for locoregionally recurrent non-small cell lung cancer (NSCLC). Materials and Methods: From 2004 to 2008, 21 patients received curative radiotherapy for locoregionally recurrent NSCLC without systemic metastasis after surgery. At the time of recurrence, the median age was 70 years (range 49∼81 years), and 19 patients were male. Most patients (n=17) were ECOG 0 or 1 performance status. The median disease-free interval was 15 months. Distribution of recurrence sites were mediastinal lymph nodes (n=10), ipsilateral hilar lymph nodes (n=4), ipsilateral lung parenchyma (n=4), bronchial stump (n=2) and ipsilateral supraclavicular lymph nodes (n=1). Radiotherapy was administered (median 66 Gy, range 59.4∼70 Gy) by a three-dimensional conformal technique. Thirteen patients received chemotherapy concurrently during radiotherapy. Pulmonary function test (PFT) was also used to detect lung function change before and after radiation. Results: The median survival and 1and 2-year survival rates were 17 months, 68% and 34%, respectively. Concurrent chemotherapy did not affect postrecurrence overall survival (p=0.183). Seven patients (33% of all patients) had re-progression within the radiation field at a median time of 4 months after completion of radiation. Diffusing lung capacity for carbon monoxide of lung after radiotherapy decreased significantly compared with pre-radiotherapy status (p=0.033). Radiation pneumonitis of any grade was seen in 11 patients. Three patients died of pulmonary complications: one of bacterial pneumonia, one of exacerbation of underlying interstitial pulmonary fibrosis and one of radiation pneumonitis. Conclusion: This retrospective study showed that curative radiotherapy for locoregionally recurrent NSCLC resulted in a median survival of 17 months and a 2-year survival rate of 34%, which is comparable to other studies. Patients suitable for curative radiotherapy for recurrent NSCLC could be treated aggressively, such as using high dose radiation with or without chemotherapy. However, pre-radiotherapy lung function should be carefully evaluated to avoid serious post-treatment lung damage considering poor lung function of post-resection patients. (J Lung Cancer 2011;10(1):37 󰠏 43)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 1","pages":"37-43"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.37","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutational and Expressional Analysis of DOK2 Gene in Non-small Cell Lung Cancers","authors":"N. Yoo, M. S. Kim, S. Lee","doi":"10.6058/JLC.2011.10.1.26","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.26","url":null,"abstract":"Purpose: Mounting evidence indicates that perturbation of tyrosine phosphorylation is implicated in the development of many human diseases, including cancers. Docking proteins (DOKs) are tyrosine-phosphorylated proteins that negatively regulate tyrosine kinase signaling and they are considered to be tumor suppressors. Deletion and the altered expression of the DOK2 gene have been studied in leukemias and lung cancers. However, the somatic mutation status of the DOK2 gene has not been studied in lung cancers. The aim of this study was to see whether alterations of DOK2 protein expression and somatic mutation of the DOK2 gene are present in human non-small cell lung cancer (NSCLC). Materials and Methods: We analyzed DOK2 somatic mutation in 45 NSCLCs (23 adenocarcinomas (AD) and 22 squamous cell carcinomas (SCC) by single-strand conformation polymorphism (SSCP). We examined the DOK2 protein expression in 45 NSCLCs by immunohistochemistry. Results: SSCP analysis revealed no evidence of somatic mutation in the DNA sequences encoding the DOK2 gene in the 45 NSCLCs. Among the informative cases, 27% and 21% of the ADs and SCCs showed allelic loss in the DOK2 locus, respectively. On the immunohistochemistry, DOK2 protein was expressed in the normal bronchial epithelial cells, while it was lost in 10 (22%) of the NSCLCs. Conclusion: Our data indicates that DOK2 is altered in NSCLC at the expressional level, but not at the mutational level. The data also suggests that loss of the expression of DOK2 might play roles in NSCLC development by possibly altering tyrosine kinase signaling. (J Lung Cancer 2011;10(1):26 �� 31)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 1","pages":"26-31"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.26","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Micronodular Thymoma with Lymphoid Stroma: A Case Report","authors":"H. Song, Joungho Han, Taesung Kim","doi":"10.6058/JLC.2011.10.1.56","DOIUrl":"https://doi.org/10.6058/JLC.2011.10.1.56","url":null,"abstract":"Micronodular thymoma with lymphoid stroma (MNT) is an extremely rare tumor and has not been reported in Korea. Herein, we report a case of MNT diagnosed in a 75 year-old male. The mass was incidentally identified on thoracic computer tomography (CT) during work-up for a cardiac mass. The resected thymic mass was ovoid and solid measuring 3.5×3 cm in size and showed homogenously white tan, solid and firm cut surface. Microscopically, the tumor had a thin fibrous capsule except small foci of invasion to thymic adipose tissue, and consisted of characteristic multiple discrete epithelial nodules in abundant lymphoid stroma. The epithelial nests anastomosed each other, forming a vague cord-like structure. The cells in the epithelial nests were bland, spindle to oval shape with relatively abundant cytoplasm, slightly vesicular chromatin and one definite nucleolus. The lymphoid stroma contained prominent germinal centers. No evidence of recurrence or metastasis has been found within 4 years of surgery.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 1","pages":"56-58"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2011.10.1.56","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71161869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.","authors":"J Clay Callison,&nbsp;Ronald C Walker,&nbsp;Pierre P Massion","doi":"10.6058/jlc.2011.10.2.69","DOIUrl":"https://doi.org/10.6058/jlc.2011.10.2.69","url":null,"abstract":"<p><p>Lung cancer is a deadly disease that is difficult to diagnose and even more difficult to treat effectively. Many pathways are known to affect tumor growth, and targeting these pathways provides the cornerstone by which cancer is treated. Somatostatin receptors (SSTR) are a family of G protein coupled receptors that signal to alter hormonal secretion, increase apoptosis, and decrease cellular proliferation. These receptors are expressed in many normal and malignant cells, including both small cell and non-small cell lung cancer. Synthetic analogs of SSTRs are commercially available, but their effects in lung cancer are still largely uncertain. Signaling pathway studies have shown that SSTRs signal through phosphotyrosine phosphatases to induce apoptosis as well as to decrease cell proliferation. Radiolabeled SSTR2 analogs are utilized for radiographic imaging of tumors, which, when combined with positron emission tomography-computed tomography (PET-CT) may improve detection of lung cancer. These radiolabeled SSTR2 analogs also hold promise for targeted chemotherapy as well as radiotherapy. In this review, we summarize what is known about SSTRs and focus our discussion on the knowledge as it relates to lung cancer biology, as well as discuss current and future uses of these receptors for imaging and therapy of lung cancer.</p>","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"10 2","pages":"69-76"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/jlc.2011.10.2.69","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33039304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgG4-Related Lung Disease Presenting as a Consolidative Mass: A Case Report","authors":"H. Park, Joungho Han, G. Kang, C. Yi, M. Chung","doi":"10.6058/JLC.2010.9.2.103","DOIUrl":"https://doi.org/10.6058/JLC.2010.9.2.103","url":null,"abstract":"Immunoglobulin G4 (IgG4)-related sclerosing disease involving the lung is a rare condition, and this is characterized by an elevated serum IgG4 level, fibrotic inflammation with numerous IgG4-positive plasma cells and a response to steroid therapy. We present here a case of pulmonary IgG4-related disease in a 75-year-old man who presented with cough and yellowish sputum for the previous 3 months. The chest images showed a consolidative mass in the right lower lobe that suggested mucinous bronchioloalveolar carcinoma. The wedge resected specimen revealed an ill-defined gray-tan, firm lesion. Microscopically, the lesion showed a diffuse lymphoplasmacytic infiltration with irregular fibrosis in the alveolar interstitium and bronchovascular bundles. There were numerous IgG4-positve plasma cells and these cells were diffusely distributed. The serum IgG4 level was elevated on the postoperative check-up (249 mg/dL). After corticosteroid therapy for 7 months, the patient’s symptoms and radiologic abnormalities were improved. (J Lung Cancer 2010;9(2):103 �� 105)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"9 1","pages":"103-105"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2010.9.2.103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71160837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}